HER2 Expression in Gastric and Oesophageal Cancer: a Meta-analytic Review

Overview

Journal J Gastrointest Oncol

Date 2015 Apr 2

PMID 25830034

Citations 12

Authors

Vinayak Nagaraja

Guy D Eslick

Affiliations

Soon will be listed here.

Abstract

Background: Since the advent and the success of adjuvant medical therapy for human epidermal growth factor receptor 2 (HER2)-positive breast cancer in the form of trastuzumab there has been increasing interest in the development of similar therapies in other solid organ malignancies including gastric cancer and oesophageal cancer. Over the years, multiple observational studies have been inconsistent. Several meta-analyses have been published looking at the association between HER2 and gastric cancer and oesophageal cancer. This review aims to summarize the meta-analytic evidence for the association between HER2 in gastric and oesophageal cancer.

Methods: A systematic search was conducted using MEDLINE, PubMed, EMBASE, Current Contents Connect, Cochrane Library, Google Scholar, Science Direct, and Web of Science.

Results: Of the articles selected, only nine studies met full criteria. Six of them reviewed the role of HER2 in gastric cancer and the remaining three reviewed its role in oesophageal cancer.

Conclusions: The current evidence regarding the role of HER2 is unclear. However, it clearly plays a key role in the pathogenesis of gastric and oesophageal carcinomas. Targeted therapy towards this subgroup (despite variable frequency and association with survival) would offer a mortality benefit and improve survival.

Citing Articles

The value of the radiological diameter-to-thickness ratio in patients with HER2-positive resectable advanced gastric cancer: implications for long survival and stage migration.

Hou B, Guo T, Gao J, Cao Y, Lu H, Ma T Abdom Radiol (NY). 2024; 49(11):3797-3810.

PMID: 38907839 DOI: 10.1007/s00261-024-04420-7.

HER-2 positivity is a high risk of recurrence of stage I gastric cancer.

Kim S, Kim Y, Chung W Korean J Intern Med. 2021; 36(6):1327-1337.

PMID: 34428882 PMC: 8588971. DOI: 10.3904/kjim.2020.243.

Overview of current targeted therapy in gallbladder cancer.

Song X, Hu Y, Li Y, Shao R, Liu F, Liu Y Signal Transduct Target Ther. 2020; 5(1):230.

PMID: 33028805 PMC: 7542154. DOI: 10.1038/s41392-020-00324-2.

Radiosensitization of HER2-positive esophageal cancer cells by pyrotinib.

Lian X, Zhu C, Lin H, Gao Z, Li G, Zhang N Biosci Rep. 2020; 40(2).

PMID: 32022229 PMC: 7029153. DOI: 10.1042/BSR20194167.

YES1 activation induces acquired resistance to neratinib in HER2-amplified breast and lung cancers.

Takeda T, Yamamoto H, Suzawa K, Tomida S, Miyauchi S, Araki K Cancer Sci. 2019; 111(3):849-856.

PMID: 31856375 PMC: 7060468. DOI: 10.1111/cas.14289.

References

Han J, Meng Q, Liu X, Xi Q, Zhuang Q, Wu G . Lack of effects of HER-2/neu on prognosis in colorectal cancer: a meta-analysis. Asian Pac J Cancer Prev. 2014; 15(14):5551-6. DOI: 10.7314/apjcp.2014.15.14.5551. View

Li C, Liu D, Ye L, Huang L, Jaiswal S, Li X . HER-2 overexpression and survival in colorectal cancer: a meta-analysis. J Zhejiang Univ Sci B. 2014; 15(6):582-9. PMC: 4116855. DOI: 10.1631/jzus.B1300258. View

Wang S, Zheng G, Chen L, Xiong B . Effect of HER-2/neu over-expression on prognosis in gastric cancer: a meta-analysis. Asian Pac J Cancer Prev. 2012; 12(6):1417-23. View

Penault-Llorca F, Bilous M, Dowsett M, Hanna W, Osamura R, Ruschoff J . Emerging technologies for assessing HER2 amplification. Am J Clin Pathol. 2009; 132(4):539-48. DOI: 10.1309/AJCPV2I0HGPMGBSQ. View

Luo H, Han L, Jiang Y . Meta-analysis of six randomized control trials of chemotherapy plus anti-HER monoclonal antibody for advanced gastric and gastroesophageal cancer. Asian Pac J Cancer Prev. 2014; 15(13):5343-8. DOI: 10.7314/apjcp.2014.15.13.5343. View

Aumayr K, Soleiman A, Sahora K, Schindl M, Werba G, Schoppmann S . HER2 gene amplification and protein expression in pancreatic ductal adenocarcinomas. Appl Immunohistochem Mol Morphol. 2013; 22(2):146-52. DOI: 10.1097/PAI.0b013e31828dc392. View

Chua T, Merrett N . Clinicopathologic factors associated with HER2-positive gastric cancer and its impact on survival outcomes--a systematic review. Int J Cancer. 2011; 130(12):2845-56. DOI: 10.1002/ijc.26292. View

DerSimonian R, Laird N . Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3):177-88. DOI: 10.1016/0197-2456(86)90046-2. View

Parkin D, Bray F, Ferlay J, Pisani P . Global cancer statistics, 2002. CA Cancer J Clin. 2005; 55(2):74-108. DOI: 10.3322/canjclin.55.2.74. View

10.

Gu J, Zheng L, Wang Y, Zhu M, Wang Q, Li X . Prognostic significance of HER2 expression based on trastuzumab for gastric cancer (ToGA) criteria in gastric cancer: an updated meta-analysis. Tumour Biol. 2014; 35(6):5315-21. DOI: 10.1007/s13277-014-1693-7. View

11.

Teplinsky E, Muggia F . Targeting HER2 in ovarian and uterine cancers: challenges and future directions. Gynecol Oncol. 2014; 135(2):364-70. DOI: 10.1016/j.ygyno.2014.09.003. View

12.

Gowryshankar A, Nagaraja V, Eslick G . HER2 status in Barrett's esophagus & esophageal cancer: a meta analysis. J Gastrointest Oncol. 2014; 5(1):25-35. PMC: 3904023. DOI: 10.3978/j.issn.2078-6891.2013.039. View

13.

Hsu J, Chen T, Tseng J, Chiu C, Liu K, Yeh C . Impact of HER-2 overexpression/amplification on the prognosis of gastric cancer patients undergoing resection: a single-center study of 1,036 patients. Oncologist. 2011; 16(12):1706-13. PMC: 3248769. DOI: 10.1634/theoncologist.2011-0199. View

14.

Jorgensen J, Hersom M . HER2 as a Prognostic Marker in Gastric Cancer - A Systematic Analysis of Data from the Literature. J Cancer. 2012; 3:137-44. PMC: 3319979. DOI: 10.7150/jca.4090. View

15.

Serpa Neto A, Tobias-Machado M, Wroclawski M, Fonseca F, Teixeira G, Amarante R . Her-2/neu expression in prostate adenocarcinoma: a systematic review and meta-analysis. J Urol. 2010; 184(3):842-50. DOI: 10.1016/j.juro.2010.04.077. View

16.

Hofmann M, Stoss O, Shi D, Buttner R, van de Vijver M, Kim W . Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology. 2008; 52(7):797-805. DOI: 10.1111/j.1365-2559.2008.03028.x. View

17.

Liang J, Zhang J, Zhang T, Zheng Z . Clinicopathological and prognostic significance of HER2 overexpression in gastric cancer: a meta-analysis of the literature. Tumour Biol. 2014; 35(5):4849-58. DOI: 10.1007/s13277-014-1636-3. View

18.

Wu S, Ma C, Yang Y . The prognostic value of HER-2/neu overexpression in colorectal cancer: evidence from 16 studies. Tumour Biol. 2014; 35(11):10799-804. DOI: 10.1007/s13277-014-2376-0. View

19.

Chen C, Yang J, Hu T, Xu T, Yan G, Hu S . Prognostic role of human epidermal growth factor receptor in gastric cancer: a systematic review and meta-analysis. Arch Med Res. 2013; 44(5):380-9. DOI: 10.1016/j.arcmed.2013.07.001. View

20.

Kurokawa Y, Matsuura N, Kimura Y, Adachi S, Fujita J, Imamura H . Multicenter large-scale study of prognostic impact of HER2 expression in patients with resectable gastric cancer. Gastric Cancer. 2014; 18(4):691-7. DOI: 10.1007/s10120-014-0430-7. View